Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

 Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Shots:

  • Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D
  • The US FDA granted PR to the therapy, allowing the agency to take action on NDA within 6mos. of acceptance compared to 10mos. under standard review
  • Finerenone is an investigational, non-steroidal, selective MRA and has showed a reduction in harmful effects of MR overactivation. The therapy has demonstrated positive kidney and CV outcomes in patients with CKD and T2D

Click here ­to­ read full press release/ article | Ref: BusinessWire | Image: Market Screener

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post